Storage Stability
FGF-2 (basic fibroblast growth factor, bFGF) is the prototypic member of the fibroblast growth factor family and one of the most potent angiogenic and wound-healing peptides known. It exists in multiple isoforms (18-34 kDa) generated from alternative translation initiation, signals through FGFR1-4, and drives endothelial cell proliferation, smooth muscle cell migration, collagen synthesis, and neuronal survival.
Mechanism of Action
- Binds FGFR1 extracellular domain in a 2:2:2 ternary complex with heparin/HSPG, driving receptor dimerization and transphosphorylation
- Activates RAS/MAPK, PI3K/Akt, PLCgamma, and STAT3 pathways; drives G1 to S phase cell cycle progression
- Potent angiogenic factor: stimulates endothelial cell proliferation, migration, tube formation, and MMP-2 secretion for basement membrane degradation
- Promotes fibroblast proliferation and collagen synthesis; accelerates granulation tissue formation in wounds
- Neuroprotective: FGFR1 activation in neurons activates PI3K/Akt survival pathways; FGF-2 supports dopaminergic and cholinergic neuron survival
Research Findings
- FGF-2 was the first angiogenic growth factor characterized (1984, Shing/Folkman lab); foundational work that established the angiogenesis field
- Recombinant bFGF (Trafermin/Fiblast) approved in Japan for pressure ulcers and burns; accelerates wound closure in clinical trials
- FGF-2 combined with fibrin or collagen scaffold accelerated diabetic ulcer healing in randomized trials
- FGF-2 intracoronary infusion in Phase II trials (TRAFFIC, FIRST): improved perfusion in severe coronary artery disease but did not meet primary endpoints in Phase III
- FGF-2 biomarker: elevated in diverse cancers (bladder, renal, breast); correlates with tumor angiogenesis and poor prognosis
Research Protocols
- Wound healing (Japan-approved Trafermin): 100-400 mcg per wound spray, once or twice daily for 4-8 weeks on chronic wounds
- In vitro angiogenesis: 10-100 ng/mL in endothelial tube formation or BrdU proliferation assay
- Subcutaneous matrigel plug: 500 ng/plug FGF-2 to assess in vivo angiogenic potency in mice
- Coronary angiogenesis trial: 0.33-36 mcg/kg/min intracoronary infusion for 20 minutes; measure perfusion by MRI
Interactions
- Heparin and heparan sulfate: required co-ligand for FGFR signaling; heparin analogs can modulate FGF-2 bioavailability
- VEGF: synergistic angiogenic effect; co-administration produces greater vessel density than either alone in matrigel assays
- Suramin (FGFR antagonist): blocks FGF-2 angiogenesis; used as anti-tumor tool compound
Safety Profile
Recombinant FGF-2 (Trafermin) approved in Japan; well tolerated topically with minimal systemic absorption. IV FGF-2 in coronary trials caused transient proteinuria and flushing at high doses. Pro-angiogenic properties theoretically concerning in occult tumor settings.
Legal & Regulatory
Trafermin (Fiblast): approved in Japan for chronic wounds and burns. Investigational elsewhere.
Ready to dose FGF-2 (Basic FGF)?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
More in Tissue Repair
View all →